Search

Displaying results 4671 - 4680 of 7186 in total
  1. Drug

    Daledalin

    go.drugbank.com/drugs/DB09189
    Experimental

    It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.

  2. Drug

    Fenthion

    go.drugbank.com/drugs/DB11412
    ExperimentalVet approved

    Fenthion is listed as a restricted use compound by the United States Environmental Protection Agency due to its potential to cause cholinesterase inhibition in humans and animals. … Its mode of action is explained by cholinesterase enzyme inhibition, which is similar to other organophosphates.

    Synonyms: O,O-Dimethyl O-4-methylthio-m-tolyl phosphorothioate, O,O-Dimethyl O-[3-methyl-4-(methylsulfanyl)phenyl] thiophosphate
  3. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    [A31948] It was originated in Japan by Kyowa Hakko, it is submitted for FDA approval and it is currently available in some Asian countries like India and Japan.[L1385, L1386]

  4. Drug

    Eslicarbazepine

    go.drugbank.com/drugs/DB14575
    Approved

    Eslicarbazepine is an anti-epileptic medication available commercially as eslicarbazepine acetate.

  5. Drug

    Desloratadine

    go.drugbank.com/drugs/DB00967
    ApprovedInvestigational

    Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a l...

    Mixtures: NEUMOLEX® NF
  6. Drug

    Alunacedase alfa

    go.drugbank.com/drugs/DB15736
    Investigational

    Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.

  7. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  8. Drug

    Carmofur

    go.drugbank.com/drugs/DB09010
    ApprovedWithdrawn

    Carmofur has been known to induce leukoencephalopathy.

  9. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  10. Drug

    Clenoliximab

    go.drugbank.com/drugs/DB06241
    Experimental

    Clenoliximab is a chimeric monoclonal antibody from _Macaca irus_ against CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.